🇺🇸 FDA
Patent

US 10195214

Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors

granted A61KA61K31/496A61K31/575

Quick answer

US patent 10195214 (Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors) held by Corcept Therapeutics Incorporated expires Mon Jan 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Corcept Therapeutics Incorporated
Grant date
Tue Feb 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K31/496, A61K31/575, A61K31/7048, A61K45/06